CAS 1330782-76-7 appears in our catalog under these names: Simurosertib/ 99.93% (existing batch purity), Simurosertib (TAK–931), Simurosertib, Simurosertib 99%, Simurosertib, 99%, 99%. Offered by: TargetMol, GLPBio, Biosynth, Ambeed, Chemat. Available pack sizes: 1mg, 2mg, 5mg, 10mg, 25mg, 50mg, 100mg, 10mM (in 1ml dmso).
Simurosertib is an orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, simurosertib binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells.
Source: ChEBI
| Molecular formula | C17H19N5OS |
|---|---|
| Molecular weight | 341.4 g/mol |
| IUPAC name | 2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one |
| InChIKey | XGVXKJKTISMIOW-ZDUSSCGKSA-N |
| SMILES | CC1=C(C=NN1)C2=CC3=C(S2)C(=O)NC(=N3)[C@@H]4CC5CCN4CC5 |
Computed by PubChem (NCBI)